What is Elotuzumab?
Elotuzumab, also known as HuLuc63, is a monoclonal antibody being developed by Bristol-Myers Squibb in collaboration with AbbVie. Elotuzumab binds to SLAMF7, also known as CS1, a substance that is on the surface of myeloma cells. This agent is given as an intravenous infusion.
The Multiple Myeloma Research Consortium (MMRC) has played a role in this drug’s development and is currently facilitating several trials evaluating elotuzumab in combination with other myeloma agents.